The state of Illinois currently has 16 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Northwestern University, Chicago, Illinois +2 locations
Conditions: Progressive Pulmonary Fibrosis
Pulmonary Fibrosis Foundation Community Registry
Recruiting
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Pulmonary Fibrosis Foundation, Chicago, Illinois
Conditions: Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis
Explanted Lung Tissues With Pulmonary Fibrosis
Recruiting
The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: The University of Chicago, Chicago, Illinois
Conditions: Pulmonary Fibrosis
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: GenHarp Clinical Solutions, Chicago, Illinois
Conditions: Idiopathic Pulmonary Fibrosis